A Drug Interaction Study of LY3154207 in Healthy Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
The main purpose of this study is to learn more about the safety and side effects of LY3154207 and fluconazole (anti-fungal medication), when taken together by healthy participants. The study will last from nine to 11 weeks for each participant.
Key facts
- Study ID
- NCT03942029
- Run by
- Eli Lilly and Company
- People needed
- 36
- Starts
- 2019-06-21
- Expected to finish
- 2019-12-28
- Last updated by the study team
- 2020-01-18
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Have a body mass index (BMI) of 18 to 35 kilogram per meter square (kg/m²)
- Have clinical laboratory test results within acceptable range for the population
You may not qualify if…
- Have consumed grapefruits or grapefruit-containing products, Seville oranges or Seville orange-containing products, star fruits or star fruit-containing products within 7 days prior to dosing or intend to consume during the study
- Intend to use over-the-counter or prescription medication (with exception of hormonal contraceptives and acetaminophen), including herbal preparations containing St. John's wort, kava, garlic, ginger, ginkgo biloba, or guarana, within 14 days prior to Check-in and during the study
- Use of any drugs or substances that are known inducers and/or inhibitors of cytochrome P450 (CYP) 3A within 14 days prior to the administration of study drug and during the study
- Have evidence of active renal disease (eg, diabetic renal disease, polycystic kidney disease) or an estimated creatinine clearance of < 80 milliliters per minute (mL/minute), calculated using the Chronic Kidney Disease Epidemiology Collaboration equation
Where it is running
- Covance Clinical Research Inc — Daytona Beach, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.